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This open-label, single-site, pilot study evaluated the therapeutic usefulness of topiramate in five children with typical absence
seizures defined as loss of awareness associated with 3 Hz spike-wave activity on 24 hour ambulatory electroencephalo-
gram (EEG). The children were previously untreated or treated unsuccessfully using other antiepileptic medication. Topiramate
was initiated at a dose of 1 mg kg−1day−1, titrated twice weekly in 1 mg kg−1day−1 increments to 12 mg kg−1day−1 or
individual maximally tolerated dose. Response was assessed after 6 weeks with ambulatory EEG monitoring and patient/parent
record of seizure counts. All children completed the study. One previously untreated child became seizure-free on 5 mg kg−1
day−1 topiramate, with no residual spike-wave activity at the final visit. In two patients, the frequency of seizures decreased
in the early phases of titration, but rose to baseline levels as the topiramate dose was increased. With a reduction in dose
to 6 mg kg−1day−1, seizure control improved, with substantial reductions in spike-wave activity. Seizure counts were not
improved in the two remaining patients. Transient mood changes were noted in two patients. No child was withdrawn secondary
to adverse effects. The results suggest that topiramate may be effective in childhood absence epilepsy. Controlled studies are
now required to identify the clinically optimal dose.
c© 2002 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
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INTRODUCTION
Childhood absence epilepsy is an idiopathic gener-
alized epilepsy syndrome characterized by frequent
absence seizures which take the form of brief
impairments of consciousness, usually with an abrupt
onset and offset. Absence seizures account for 2–11%
of all seizure types. In childhood absence epilepsy
they typically emerge between the ages of 5 and
10 years1, often occurring upwards of 20 times a
day2. In addition to interference with daily activities,
absences present a serious risk of accidental injury3.
Although affected children are generally of normal
intelligence, childhood absence epilepsy has the
potential to negatively impact upon learning and
academic performance.
Absence seizures generally respond promptly
to treatment with conventional antiepileptic
drugs (AEDs) such as sodium valproate and
ethosuximide1, 4. However, ethosuximide has little
effect on other seizure types. In addition, these drugs
are known to produce adverse effects in ≥50% of
patients5, 6, including somnolence, nausea, headache,
dizziness and weight gain. These specific adverse
effects are more prominent in patients receiving
polytherapy than monotherapy, while idiosyncratic
toxicities such as allergic dermatitis, pancreatitis and
agranulocytosis are also reported4. The traditional
AEDs carbamazepine and phenytoin are precluded
in some generalized epilepsy syndromes, including
childhood absence epilepsy, as these agents have been
shown to exacerbate absence seizures7, 8.
Several novel AEDs such as topiramate, lamotrigine
and gabapentin have recently been developed9. These
are expected to be at least similar in efficacy (recently
demonstrated with lamotrigine10), but preferable
in side-effect profile to the conventional portfolio
of AEDs, indicating potential use in monotherapy
applications.
Topiramate is presently indicated as both monother-
apy and adjunctive therapy in adults and children
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(aged ≥ 2 years) with partial-onset seizures or
primary generalized tonic–clonic seizures. In addition,
topiramate is indicated as adjunctive therapy for the
treatment of seizures associated with Lennox–Gastaut
syndrome in both adults and children. In randomized
controlled trials involving adults and children with
epilepsy11–15 (for review see Reference 16), topira-
mate did not appear to aggravate generalized seizures,
including absence seizures. Beneficial effect on
absence seizures was difficult to assess in such studies,
however, as seizure frequency cannot be accurately
determined by clinical evaluation alone17, 18.
To evaluate the efficacy of therapeutic agents in
absence epilepsy, exact seizure counts can be reliably
measured using 24 hour ambulatory electroencephalo-
gram (EEG). This paper describes a pilot study
utilizing EEG to evaluate the therapeutic usefulness of
topiramate in childhood absence epilepsy. The study
also aimed to generate information regarding the safe
titration rate and minimal effective dose of topiramate.
METHODS
Five children (two boys, three girls; age range 6–11.5
years) entered this open-label, single-site, pilot study.
Their demographics are shown in Table 1. Absence
seizures were the only type of seizure experienced by
all children at entry to the study. Inclusion criteria
required for the study are shown in Table 2. The
study had full approval from the local Research Ethics
Committee. Informed consent was obtained from all
parents/guardians.
Each parent was asked to keep a seizure diary for the
duration of the study. More accurate documentation
of episodes was achieved using 24 hour ambulatory
EEG following a 3 minute period of hyperventilation.
For inclusion in the study, the children were required
to have typical absence seizures characterized by
3 Hz spike-wave discharges. Runs of 3 Hz spike-wave
activity of≥3 seconds were regarded as significant for
the purpose of this study.
The protocol required previous AED therapy to
have been discontinued at least 5 days before
screening where possible. Seven days prior to the
first dose of topiramate, at the screening visit,
measurements were made of 24 hour ambulatory
EEG, electrocardiogram (ECG), haematology, blood
chemistry, urinalysis, and a full clinical evaluation
including physical examination was performed.
Patients received oral topiramate at a starting
dose of 1 mg kg−1day−1 on a twice-daily (b.i.d.)
regimen, commencing on day 1. The dose was titrated
twice weekly in 1 mg kg−1day−1 increments to
12 mg kg−1day−1 over 6 weeks, seizure freedom prior
to this dose, or the maximally tolerated dose for that
individual. On the day prior to each dose increment,
telephone contact was made with the parent. If a
patient could not tolerate a given topiramate dose
during the escalation phase, the titration time could
be extended or the dose reduced. Patients controlled
at 25 mg day−1 could receive topiramate on a once-
daily dose regimen. Haematology, blood chemistry
and urinalysis measurements were repeated on days
15, 29 and 43 (final visit, week 6) with a repeat 24 hour
ambulatory EEG taken at the final visit.
Clinical response was assessed at week 6 using
data from 24 hour ambulatory EEG monitoring and
a patient/parent diary of seizure counts. Efficacy was
calculated using EEG results as a percentage reduction
in 3 Hz spike-wave discharges of≥3 seconds. Physical
examination, medical history, ECG, haematology,
blood chemistry and urinalysis measurements were
also carried out.
RESULTS
Of the five children entering the study, three had
previously been treated unsuccessfully using one or
more AED (Table 1). Of these, two (patients 2 and 3)
had discontinued antiepileptic therapy at least 5 days
prior to screening according to the study protocol.
There was a departure from protocol in one patient
(patient 4), who was still receiving sodium valproate
at the screening visit. An attempted wean had been
made but this had led to deterioration in seizure control
after 2 weeks, prior to a complete wean of sodium
valproate. He was therefore entered into the study, and
sodium valproate was discontinued by day 13 of the
protocol.
All five children completed the study. Individual
results for each patient are presented in Table 3. One
previously untreated child (patient 1) achieved seizure
freedom on a dose of 5 mg kg−1day−1 topiramate,
with no residual spike-wave activity on 24 hour EEG
at the final visit. As clinical resolution was noted
at this dose, confirmed by EEG, topiramate was not
increased further. Subsequently this patient remained
seizure-free for 2 years and has since been weaned
from medication with no seizure recurrence.
In patients 2 and 3, absence seizures were reduced
in the early phases of titration, but increased towards
baseline levels as the topiramate dose increased
to 12 mg kg−1day−1. With a dose reduction to
6 mg kg−1day−1, seizure control improved, and
patient 2 became clinically seizure-free. Patient 3
showed maintained clinical improvement, with seizure
counts reduced by >50% (from 390 episodes at study
entry to 31 episodes at the end of the 6 week study
period). Substantial reductions in EEG spike-wave
duration were also observed for patients 2 and 3, both
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Table 1: Patient demographics.
Patient Sex Current
age
Age at onset Weight (kg) Previous medication Topiramate course
1 F 10 years,
6 months
10 years 40.25 None 5 mg kg−1day−1 led to seizure freedom,
therefore stopped titration
2 F 6 years 4 years 23.25 Sodium valproate—weaned
prior to study entry
Increased to 12 mg kg−1day−1 as per
protocol, then decreased to
6 mg kg−1day−1 over 2–3 weeks. No
change in dose thereafter. Seizure-free 2
weeks after maintenance at reduced dose
3 M 10 years,
6 months
8 years 45.00 Sodium valproate—no effect.
Ethosuximide—patient aggres-
sive. Lamotrigine— patient
aggressive, weaned off this for
the trial
Increased to 12 mg kg−1day−1 as per
protocol, then decreased to
6 mg kg−1day−1 over 2–3 weeks. No
change in dose thereafter. Seizure reduction
noted at reduced dose
4 M 7 years,
1 month
6 years 27.20 Sodium valproate—reduced by
200 mg day−1 every 5 days for
study entry. Absences increased
after 2 weeks therefore
premature study entry
Increased to 12 mg kg−1day−1 as per
protocol. Seizure frequency returned to
baseline
5 F 9 years,
2 months
4 years 27.50 None Increased to 12 mg kg−1day−1 as per
protocol. Subsequent reduction to
6 mg kg−1day−1. No change in seizure
frequency
of whom had previously been treated unsuccessfully
with other AEDs (Tables 1 and 3).
Table 2: Inclusion criteria.
Age 4–11 years
Weight ≥11.5 kg
‘Normal’ intelligence attending school
Typical absence seizures associated with spike-wave activity on
routine EEG
(≥1 spontaneous run of 3 Hz spike-wave discharges lasting
≥3 seconds)
Absence seizures
— newly diagnosed or
— inadequately controlled or
— associated with intolerable side effects on one AED
For patients 4 and 5, no improvements in seizure
counts were observed with topiramate treatment and
only minimal changes in the EEG recordings were
obtained. Patient 4 was tapered off sodium valproate
over the course of the study period. As per protocol,
sodium valproate was reduced with the intention
of a complete wean prior to the introduction of
topiramate. However, as sodium valproate was weaned
there was an apparent increase in spike-wave activity.
Topiramate was therefore introduced prior to a
complete withdrawal of sodium valproate 13 days into
the protocol. The introduction of topiramate returned
the seizure frequency to baseline but there was no
further improvement seen. The patient subsequently
became seizure-free on a combination of sodium
valproate and lamotrigine. Patient 5 was previously
untreated. An attempt at dosage reduction from 12 to
6 mg kg−1day−1 (seen to reduce seizure frequency
in patients 2 and 3) did not improve the clinical
outcome for this patient. Seizures were subsequently
resistant to sodium valproate, but responded to high
dose lamotrigine.
Transient mood changes were also reported in these
two children, but no alterations in topiramate dose
were required as a result, and in both they resolved
spontaneously with no deviation from the protocol of
titration. No other adverse events were observed in the
study as a whole.
DISCUSSION
There is general agreement that childhood absence
epilepsy has a favourable prognosis19. Treatment
is often effective with conventional AEDs, but can
be complicated by undesirable side effects. The
availability of newer AEDs with the possibility
of fewer adverse effects should lead to a steady
improvement in therapeutic outcome. Monotherapy is
the favoured approach to treatment. Lamotrigine is one
of the newer agents recently shown to be effective
as monotherapy in the treatment of absence epilepsy
associated with 3 Hz spike-wave in comparison with
placebo10.
Pre-clinical studies using the novel AED topiramate
indicate a broad spectrum of anticonvulsant activity
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Table 3: Response to topiramate in children with absence seizures.
24 hour EEG
Previous Topiramate (spike-wave duration)
Patient antiepileptic Clinical dose total
no. drugs result (mg kg−1day−1) Baseline Final visit
1 0 Seizure-free 5 18 min, 24 s None
2 1 Seizure-free 6 28 min, 41 s 3 min, 36 s
3 3 >50% 6 44 min, 50 s 19 min, 10 s
reduction
4 1 No change 12 9 min, 58 s 18 min, 41 s
(20 min, 59 s)a
5 0 No change 12–6 23 min, 2 s 17 min, 58 s
a Patient taking sodium valproate at first EEG and weaned from sodium valproate at second EEG.
with multiple mechanisms of action20. Topiramate
exhibits a favourable pharmacokinetic profile in
humans, with rapid absorption, long duration of action
and minimal interaction with other AEDs16. The
present study attempts to evaluate the therapeutic
usefulness of topiramate as monotherapy in five
children with typical absence seizures. One previously
untreated child became seizure-free, and seizure
rates were reduced dramatically in two (one of
whom became clinically seizure-free) whose previous
AED therapy had failed. No deterioration in seizure
frequency was apparent in any of the five children that
could be attributed to treatment with topiramate.
In this study, the minimal effective topiramate
dose was 5 mg kg−1day−1. Rapid dose escalation
(1 mg kg−1day−1 increments twice weekly) was well
tolerated. This may be presumed to be in contrast
to experience in add-on studies of topiramate in
generalized epilepsy and Lennox–Gastaut syndrome,
where there was a relatively higher prevalence
of central nervous system side effects where the
titration had been more rapid13, 15. Controlled stud-
ies are now required, using gradual titration, to
identify the clinically optimal dose of topiramate.
Glauser16 has suggested a starting dose for children
of 0.5–1.0 mg kg−1day−1, with increases of 0.5–
1.0 mg kg−1day−1 every 1–2 weeks.
Efficacy, adverse event profiles and patient accep-
tance will be major contributory factors in determining
the future roles of the newer AEDs, not least so
in the paediatric population. Topiramate already has
a role in the treatment of partial-onset epilepsy,
generalized tonic–clonic seizures and Lennox–Gastaut
syndrome. Preliminary data from the present study
suggest that topiramate may also be useful for the
treatment of childhood absence epilepsy, and certainly
does not appear to be detrimental with regard to this
seizure type.
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